Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease was first identified in Wuhan, China in December 2019, and spread globally, resulting in the on-going 2019–20 coronavirus pandemic. Symptoms of COVID-19 include fever, cough, fatigue, loss of smell, difficulty in breathing, persistent chest pain, confusion, difficulty in walking, and bluish skin. The majority of cases result in mild symptoms. The virus is spread between people with close contacts, via small droplets produced by coughing, sneezing, or talking. People may infect by touching the contaminated surfaces and then touching their faces, eyes, and nose. Diagnosis can be done by real-time reverse transcription-polymerase chain reaction (rRT-PCR) from a nasopharyngeal swab. Chest CT imaging also helps with diagnosis in individuals. Recommended measures to prevent infection include frequent hand washing, maintaining physical distance from others (especially from those with symptoms), covering coughs, and keeping unwashed hands away from the face. There is no vaccine or specific antiviral treatment for COVID-19. Management of infection involves the treatment of symptoms, supportive care, isolation, and experimental measures. The World Health Organization (WHO) declared the 2019–20 coronavirus outbreak as a Public Health Emergency of International Concern (PHEIC) on 30 January 2020 and a pandemic on 11 March 2020.
Pathogenesis: The SARS-CoV-2 is a β-coronavirus, which is enveloped non-segmented positive-sense RNA virus (subgenus sarbecovirus, Orthocoronavirinae subfamily). Coronaviruses (CoV) are divided into four genera, including α−/β−/γ−/δ-CoV. α- and β-CoV are able to infect mammals, while γ- and δ-CoV tend to infect birds. It was found that the genome sequence of SARS-CoV-2 is 96.2% identical to a bat CoV RaTG13, where it shares 79.5% identity to SARS-CoV. It is clear now that SARS-CoV-2 could use angiotensin-converting enzyme 2 (ACE2), the same receptor as SARS-CoV to infect humans.
We are especially interested in papers that explore the issues:
Submission Process
Please visit Instruction for author’s page to know more about article formatting and guidelines: https://www.hilarispublisher.com/infectious-diseases-and-medicine/instructionsforauthors.html
Corona research fund world-wide details
https://www.fic.nih.gov/ResearchTopics/Pages/infectiousdiseases-coronavirus-cov.aspx
https://www.researchconnect.eu/coronavirus/
https://www.catalyze-group.com/covid-19-grants-and-funding/
https://wellcome.ac.uk/what-we-do/our-work/coronavirus-covid-19
Special Issue Editors
Alfredo Mena Lora
St. Anthony Hospital
USA
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease was first identified in Wuhan, China in December 2019, and spread globally, resulting in the on-going 2019–20 coronavirus pandemic. Symptoms of COVID-19 include fever, cough, fatigue, loss of smell, difficulty in breathing, persistent chest pain, confusion, difficulty in walking, and bluish skin. The majority of cases result in mild symptoms. The virus is spread between people with close contacts, via small droplets produced by coughing, sneezing, or talking. People may infect by touching the contaminated surfaces and then touching their faces, eyes, and nose. Diagnosis can be done by real-time reverse transcription-polymerase chain reaction (rRT-PCR) from a nasopharyngeal swab. Chest CT imaging also helps with diagnosis in individuals. Recommended measures to prevent infection include frequent hand washing, maintaining physical distance from others (especially from those with symptoms), covering coughs, and keeping unwashed hands away from the face. There is no vaccine or specific antiviral treatment for COVID-19. Management of infection involves the treatment of symptoms, supportive care, isolation, and experimental measures. The World Health Organization (WHO) declared the 2019–20 coronavirus outbreak as a Public Health Emergency of International Concern (PHEIC) on 30 January 2020 and a pandemic on 11 March 2020.
Pathogenesis: The SARS-CoV-2 is a β-coronavirus, which is enveloped non-segmented positive-sense RNA virus (subgenus sarbecovirus, Orthocoronavirinae subfamily). Coronaviruses (CoV) are divided into four genera, including α−/β−/γ−/δ-CoV. α- and β-CoV are able to infect mammals, while γ- and δ-CoV tend to infect birds. It was found that the genome sequence of SARS-CoV-2 is 96.2% identical to a bat CoV RaTG13, where it shares 79.5% identity to SARS-CoV. It is clear now that SARS-CoV-2 could use angiotensin-converting enzyme 2 (ACE2), the same receptor as SARS-CoV to infect humans.
We are especially interested in papers that explore the issues:
Submission Process
Please visit Instruction for author’s page to know more about article formatting and guidelines: https://www.hilarispublisher.com/infectious-diseases-and-medicine/instructionsforauthors.html
Corona research fund world-wide details
https://www.fic.nih.gov/ResearchTopics/Pages/infectiousdiseases-coronavirus-cov.aspx
https://www.researchconnect.eu/coronavirus/
https://www.catalyze-group.com/covid-19-grants-and-funding/
https://wellcome.ac.uk/what-we-do/our-work/coronavirus-covid-19
Special Issue Editors
Alfredo Mena Lora
St. Anthony Hospital
USA
Journal of Infectious Diseases and Medicine received 59 citations as per Google Scholar report